IR InformationSummary of Q&A Session for Management Presentation on Feb 27 2025

IR InformationNotice Concerning Change in Equity-Method Affiliate (Becoming a Consolidated Subsidiary)

IR InformationPresentation Materials for Management Presentation on Feb 27 2026 with Script

IR Information(Amendment) Notice Regarding Amendment to “Notice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)” and Public Notice of Commencementof Tender Offer Dueto Filingof Amendment Statement

IR InformationNotice of Formulation of Management Plan “Mission 2030” Phase 2 (FY2026–FY2028)

IR InformationPresentation Material for Management Presentation on Feb 27th 2026

IR InformationNotice of Commencement of Consideration of Spin-off of Styrene-Related Businesses

NewsFirst-time Selection as an Environmentally Sustainable Company at the ESG Finance Awards Japan

IR InformationFY2025 Third Quarter Financial Results Presentation Summary of Q&A Session

IR InformationFY2025 Third Quarter Financial Results Presentation Materials with Script

IR InformationNotice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)

IR InformationNotice Regarding Recognition of Extraordinary Losses

IR InformationNotice Regarding Personnel Changes in Executive Officers

IR InformationFY2025 Third Quarter Financial Results Presentation Materials

IR InformationFY2025 Third Quarter Summary of Consolidated Financial Results

NewsAwarded “A-” for Climate Change and “A” rating for Water Security in CDP 2025

NewsDevelopment of an ESD (endoscopic submucosal dissection) simulator model for early-stage gastrointestinal neoplasms～Results of the third “Medical Rising STAR” industry-academia collaboration project～

NewsPresident's New Year's address (excerpt from New Year's speech)